HSANZ Council congratulates Trainee Member, Katharine Lewis for the distinction of being presented with the ASH/HSANZ Abstract Award. You may have seen her oral presentation last week at the ASH conference.
This is a piece Kat wrote for HSANZ to introduce herself and her work:
My name is Katharine (Kat) Lewis and I came to Perth, WA from the UK for a lymphoma and clinical trials fellowship in late 2018, having completed my specialist examinations and almost all my haematology training in the UK prior to moving over. In my role here, I’ve gained a broad experience in lymphoma and clinical trials, and treated many patients at Linear Clinical Research and Sir Charles Gairdner Hospital as part of our clinical trials programme, as well as in the public healthcare system. I’ve been blessed to have lots of research opportunities in my fellowship role, and have recently had the privilege of leading a large international retrospective project investigating the effectiveness of HD-MTX (intravenous methotrexate) at reducing CNS relapse in patients with aggressive B-cell lymphoma at greatest risk of this complication. We included 2,300 high risk patients in the study, from 21 sites across Australia, Europe, the US and Asia. In our study, HD-MTX did not reduce rates of CNS relapse in these high risk patients. CNS relapse is a relatively rare event in aggressive B-cell lymphoma (around 10% in the highest risk patient group), and large studies are required to demonstrate small but meaningful differences in CNS prophylactic strategies in these patients. Our study is the largest to date, and provides some of the best evidence that HD-MTX is ineffective at preventing CNS relapse for this group of patients. We anticipate the results will influence global clinical practice, with fewer patients recommended to receive HD-MTX, reducing toxicity and inpatient admissions without increasing CNS relapse risk.
It’s an honour to receive the ASH-HSANZ award for the study, and to have had the opportunity to give a virtual oral presentation at ASH 2021.
PhD opportunity in Transfusion and Health Economics – Blood Synergy and Monash University
Applications close 9th January 2022
The prospective student will have the opportunity to work with a highly dynamic multidisciplinary group of clinicians and researchers within the ANZIC RC, NHMRC Blood Synergy program, Transfusion Research Unit, and Centre for Health Economics, all at Monash University. The supervisor team will include Dr Lisa Higgins, A/Prof Zoe McQuilten, and Prof Michael Reade.
Enquiries: Dr Lisa Higgins, +61 3 9903 0348, email
For further details and how to apply, visit: Jobs at Monash
HSANZ has been working hard in collaboration with RCPAQAP to create CPD opportunities for Members. These will be rolled out during the next year and below, we invite you to participate in two Haematology Case Studies for CPD.
The case studies are open to Haematologists and registrars in Australia and New Zealand. Scientists with relevant experience may also submit responses. Your answers will not be graded, and a discussion report will be emailed after your submission for self-assessment.
Each case study has three sections, completion of all three sections will award you 30 minutes towards RCPA CPD. You can access the first section of each case below; you can navigate to the subsequent sections using the links at the end of sections 1 and 2.
Closing date: 5pm AEDT, 31 January, 2022
Case Study 1 relates to abnormal haematology and biochemistry results, morphology, as well as flow cytometry and conventional Cytogenetics.
Case study 1, Section 1 of 3
Case Study 2 will explore the investigation of anaemia in a young woman.
Case Study 2, Section 1 of 3
ACORD22 Protocol Development Workshop
The Medical Oncology Group of Australia invites applications from early-career clinical cancer researchers from all oncology subspecialties based in the Asia Pacific region for our third one-week online ACORD22 Protocol Development Workshop.
ACORD’s global focus, task-oriented format, collaborative approach, and one-on-one guidance, mentoring and networking with world-renowned faculty, make it a unique career-enhancing opportunity.
Early-career clinical cancer researchers, from all specialties and disciplines, are encouraged to submit their ideas for selection
25 – 30 Sep | Online
Submission Deadline: 31 March 2022
HSANZ and ALLG Welcome the House of Representatives’ Standing Committee Report tabled in Parliament 25 November 2021
The ALLG and HSANZ welcomes the Report tabled in Parliament 25/11/21 on ‘The New Frontier - Delivering better health for all Australians: Inquiry into approval processes for new drugs and novel medical technologies in Australia’, by the House of Representatives Standing Committee on Health, Aged Care and Sport.
Medical innovation has grown exponentially in recent years. The approval processes for new medicines are very complex, and this report discusses different ways to streamline them to provide better and faster patient access to treatments; without compromising on patient safety, efficacy or cost effectiveness.
The Committee’s Report details 31 recommendations which aim to help government improve and reform the regulatory and reimbursement system; and helps pave the way for the improvements needed to provide Australians with the best possible health care now and into the future.
To read the full ALLG and HSANZ statement, click here
This article, co-authored by Steven Lane in The Hematologist provides a summary of the recent literature regarding COVID Vaccination responses in patients with blood cancers. This might be of use when providing information to patients about their options to prevent COVID19 infection.
Click here for the link
Dear Colleagues, re: The ATAGI recommendation for COVID Vaccination in immunocompromised patients
This is an important recommendation from ATAGI and is relevant to many patients with haematological disorders who may have reduced response to standard COVID vaccination regimens.
Steven Lane, President HSANZ
Click here for document
HSANZ Council was pleased to award the Albert Baikie Medal and Award for 2021 to Salvatore (Sam) Fiorenza at Blood2021. Congratulations Sam
Blood2021 on-demand Registration HSANZ sponsorships
With the completion of the live component of the Virtual Blood 2021, HSANZ would like to extend our appreciation to all members who contributed, participated and attended this meeting. The on-demand viewing for all presentations during Blood 2021 will be available for 6 months, as above.
We do realise that a proportion of our haematology constituents were not able to attend live, and therefore announce that HSANZ is offering on-demand registration sponsorship to a select number (maximum 10) of Haematology Advanced Trainees across all states who meet the following eligibility criteria:
1. You must be an active trainee member of HSANZ or have an HSANZ trainee membership submission pending approval to qualify (you must have submitted a signed application form and CV)
Applications close: 31 October 2021.
Please apply by emailing documentation to email
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, speakers will review major topics in stem cell transplantation and cell therapy, highlighting how key advances are addressing the current challenges in stem cell transplantation. The tenth webinar in this series features Professor Mohamad Mohty, who is the head of the Haematology and Cellular Therapy Department at the Saint-Antoine Hospital and the head of the translation research team at the Saint-Antoine Research Centre in Paris. He is the past president of the European Society for Blood and Marrow Transplantation (EBMT) and the current chairman of the Acute Leukaemia Working Party of the EBMT. He has published over 800 peer-reviewed articles in the field of stem cell transplantation, leukaemia and myeloma. In this webinar, Prof Mohty will be outlining the role of maintenance therapeutics following allogeneic HSCT for acute leukaemia.
Professor Mohamad Mohty – Saint-Antoine Hospital and Sorbonne University
When: Monday 11 October 2021, 5pm AEDT
For more information click here
Link to webinar:
Link to CBTCT website for all webinar recordings:
© 2023 Haematology Society of Australia & New Zealand All Rights Reserved.